Breaking

Bearish Divergence Suggests Caution For S&P 500
3 S&P 500 Charts That Point to the Next Big Move
Trump’s stance against Iran nuclear ambitions backed by vast majority of Americans: poll
Only the US military can take out Iran’s ‘most dangerous’ nuclear site
American citizen killed in Russian attack on Kyiv, State Department confirms
‘It just baffles me’: Senate Republicans sound alarm over Medicaid changes, spending in Trump megabill
Alleged Chinese scheme to influence 2020 election for Biden being probed by FBI, Senate Judiciary Committee
Homeland Security Secretary Kristi Noem hospitalized after allergic reaction

Home
Features
- View All On Demos
Buy Now
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

admin

Website

Related Posts

Silver Price Surges to US$37, Highest Value Since May 2011

Fish Mine Production and Exploration Update

Syntheia Announces Closing of Private Placement

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (408)
- Investing (1,324)
- Politics (1,618)
- Stocks (557)

Disclaimer: 2morrowgrowth.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 2morrowgrowth.com | All Rights Reserved

Top

Type above and press Enter to search. Press Esc to cancel.